Instrument Inactif

Communiqués Cytokinetics, Inc. Nasdaq

Actions

US23282W1009

Recherche biotechnologique et médicale

Cours en clôture Nasdaq
- ^USD	-

10/08	Un dirigeant de Cytokinetics cède pour 575 700 $ d'actions, selon un récent document de la SEC	MT
10/08	Cytokinetics, Incorporated : Truist Securities persiste à l'achat	ZM

Communiqués

06/08	Cytokinetics: Q2 Earnings Snapshot	AQ
06/08	Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update	AQ
30/07	Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales	AQ
23/07	Cytokinetics to Announce Second Quarter Results on August 6, 2026	AQ
17/07	Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
07/07	Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026	AQ
17/06	Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
08/06	Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program	AQ
01/06	Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany	GL
01/06	Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany	AQ
27/05	Cytokinetics to Participate in June Investor Conferences	AQ
20/05	Cytokinetics to Hold Annual Meeting of Stockholders	AQ
18/05	Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)	AQ
14/05	Cytokinetics to Host Annual Symposium on Contemporary Landscapes in Muscle Biology (CLIMB)	AQ
12/05	Cytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference	AQ
11/05	Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026	AQ
08/05	Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $805 Million	AQ
07/05	Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock	AQ
06/05	Cytokinetics Incorporated : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
05/05	Cytokinetics: Q1 Earnings Snapshot	AQ
05/05	Cytokinetics Announces Proposed Public Offering of Common Stock	AQ
05/05	Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update	AQ
05/05	Cytokinetics Announces Positive Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy	AQ
04/05	Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026	AQ
28/04	Cytokinetics Announces Nine Upcoming Presentations at the European Society of Cardiology Heart Failure 2026 Congress	AQ